The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Atrophy of the corpus collosum (CC) is associated with cognitive impairment and fatigue. Regional corpus callosum index results indicate that these associations are partially spatially segregated. PubMed, Mult Scler, 08/29/2013. (Also see Multiple Sclerosis)
Objectively measured muscle fatigue in Crohns disease. Subjects with Crohns disease had more muscle fatigue than matched healthy controls and this correlated well with self-reported fatigue. PubMed, Journal of Crohn's and Colitis, 2014 Feb;8(2):137-46. (Also see Crohns Disease)
Glycosylation status of serum in inflammatory arthritis (IA) in response to anti-TNF treatment. Anti-TNF therapy is strongly associated with a decrease in inflammatory processes and reflects the effect of anti-TNF on the immune system. Oxford Journals, 05/16/2013. (Also see Arthritis)
New Autoantibodies in early Rheumatoid Arthritis. These autoantibodies could be used as diagnosis markers in RA patients. PubMed, Arthritis Res Ther, 2013 Jul 25;15(4):R78. (Also see Rheumatoid Arthritis and Autoantibodies)
Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. Comparing the effect of second-line therapy in sarcoidosis shows that both methotrexate and azathioprine have significant steroid-sparing potency, a similar positive effect on lung function, and comparable side effects, except for a higher infection rate in the azathioprine group. CHEST Journal, September 2013 (Also see Immunosuppressants)
Current immunotherapy in Rheumatoid Arthritis. Antirheumatic drugs (DMARDs) are capable of controlling synovial inflammation and there are advantages and disadvantages of DMARD therapy with agents such as methotrexate, leflunomide, sulfasalazine, injectable gold and (hydroxy)chloroquine with biological therapies, and with the new era of kinase inhibitors. PubMed, Immunotherapy, 2013 Sep;5(9):955-74. (Also see Rheumatoid Arthritis)
Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Both aPL-negative SLE and aPL-positive non-SLE patients, without other overt neuropsychiatric disease, demonstrated high levels of cognitive impairment. PubMed, Clin Exp Rheumatol, 09/10/2013. (Also see Systemic Lupus Erythematosus and Antiphospholipid Syndrome)
Genetics and epigenetics of systemic lupus erythematosus. The role of epigenetics has recently been revealed and the identification of a growing number of gene variants associated with SLE susceptibility. PubMed, Curr Rheumatol Rep, 2013 Sep;15(9):369. (Also see Systemic Lupus Erythematosus)
The new era for the treatment of Psoriasis (PsO) and Psoriatic Arthritis (PsA). The role of IL-17 and IL-23 in the pathogenesis of PsO and PsA and their role as therapeutic targets for PsO and PsA treatment. PubMed, Autoimmun Rev, 09/07/2013. (Also see Psoriasis and Psoriatic Arthritis)
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.